Finance

Lists
600535:SHA
Tasly Pharmaceutical Group Co Ltd
13,98 CNY
-0,78%
(-0,11) 1D
16 ოქტ, 14:26:18 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600535...
Open
14,18 CNY
High
14,35 CNY
Low
13,97 CNY
Mkt. cap
20,87 მლრდ.
Avg. vol.
11,45 მლნ.
Volume
13,13 მლნ.
Dividend
2,43%
Quarterly dividend
0,09 CNY
Ex-dividend date
29 მაი. 2026
P/E ratio
17,08
52-wk high
16,24 CNY
52-wk low
12,90 CNY
EPS
0,82 CNY
Shares outstanding
1,51 მლრდ.
No. of employees
11 ათ.
Open
14,18 CNY
High
14,35 CNY
Low
13,97 CNY
Mkt. cap
20,87 მლრდ.
Avg. vol.
11,45 მლნ.
Volume
13,13 მლნ.
Dividend
2,43%
Quarterly dividend
0,09 CNY
Ex-dividend date
29 მაი. 2026
P/E ratio
17,08
52-wk high
16,24 CNY
52-wk low
12,90 CNY
EPS
0,82 CNY
Shares outstanding
1,51 მლრდ.
No. of employees
11 ათ.
News stories
From web sources and news partners
Profile
Tasly is a Chinese pharmaceutical company based in the city of Tianjin. It was established in 1994 and is notably producing traditional Chinese medicines. It has a turnover of 4 billion US dollars, 10,000 employees and is listed on the Shanghai Stock Exchange. In 2009, Chinese pharmacologist Li Lianda claimed that a key product made by Tasly was unsafe. Tasly sued Li in 2013, alleging that Li's claim was baseless and was motivated by his financial and employment relations with Guangzhou Pharmaceutical, a direct competitor of Tasly. In September 2014, the Tianjin High People's Court ruled in favour of Tasly and ordered Li to issue an apology and pay Tasly 300,000 yuan in compensation. In February 2017, Tasly announced plans to form a joint venture with American multi-level marketing company Herbalife. Wikipedia
About Tasly Pharmaceutical Group Co Ltd
CEO-
Employees10,6 ათ.
Founded1994
Headquarters-
SectorPharmaceutical industry
Websitetasly.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
2,02 მლრდ.
1,93 მლრდ.
2,16 მლრდ.
2,04 მლრდ.
Cost of goods sold
684,07 მლნ.
659,71 მლნ.
623,69 მლნ.
654,28 მლნ.
Cost of revenue
684,07 მლნ.
659,71 მლნ.
623,69 მლნ.
654,28 მლნ.
Research and development expenses
210,48 მლნ.
132,23 მლნ.
191,62 მლნ.
102,48 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
844,05 მლნ.
787,37 მლნ.
874,15 მლნ.
656,33 მლნ.
Operating expense
1,06 მლრდ.
979,15 მლნ.
1,08 მლრდ.
801,23 მლნ.
Total operating expenses
1,74 მლრდ.
1,64 მლრდ.
1,70 მლრდ.
1,46 მლრდ.
Operating income
281,20 მლნ.
286,94 მლნ.
462,71 მლნ.
580,75 მლნ.
Other non operating income
-7,57 მლნ.
-6,11 მლნ.
-733,75 ათ.
-232,24 ათ.
EBT including unusual items
248,13 მლნ.
192,46 მლნ.
461,52 მლნ.
584,82 მლნ.
EBT excluding unusual items
280,97 მლნ.
289,16 მლნ.
472,69 მლნ.
588,33 მლნ.
Income tax expense
45,36 მლნ.
123,68 მლნ.
96,97 მლნ.
64,84 მლნ.
Effective tax rate
18,28%
64,26%
21,01%
11,09%
Other operating expenses
1,56 მლნ.
53,20 მლნ.
17,23 მლნ.
42,82 მლნ.
Net income
209,68 მლნ.
120,59 მლნ.
370,24 მლნ.
522,44 მლნ.
Net profit margin
10,37%
6,26%
17,10%
25,66%
Earnings per share
-
-
-
-
Interest and investment income
14,77 მლნ.
14,84 მლნ.
14,04 მლნ.
11,58 მლნ.
Interest expense
-7,28 მლნ.
-5,44 მლნ.
-3,33 მლნ.
-5,30 მლნ.
Net interest expenses
7,49 მლნ.
9,39 მლნ.
10,71 მლნ.
6,29 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
380,28 მლნ.
380,23 მლნ.
555,99 მლნ.
663,57 მლნ.
Gain or loss from assets sale
5,21 მლნ.
-8,61 მლნ.
-
-409,04 ათ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები